|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awardedPatent
|
CRISPR gene editing methods
|
|
gptkbp:CEO
|
gptkb:John_Leonard
|
|
gptkbp:clinicalTrialPhase
|
NTLA-2001 for transthyretin amyloidosis
NTLA-2002 for hereditary angioedema
NTLA-5001 for acute myeloid leukemia
|
|
gptkbp:collaboratesWith
|
gptkb:Novartis
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
CRISPR gene editing
|
|
gptkbp:foundedYear
|
2014
|
|
gptkbp:founder
|
gptkb:Jennifer_Doudna
gptkb:Derrick_Rossi
gptkb:John_Leonard
gptkb:Rodger_Novak
|
|
gptkbp:hasCompany
|
true
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Intellia Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:leader
|
gptkb:David_Morrissey
gptkb:Carsten_Brunn
gptkb:David_Grayzel
gptkb:David_Lebwohl
gptkb:Diana_Hausman
gptkb:Frank_Verwiel
gptkb:Glenn_Goddard
gptkb:John_Leonard
gptkb:John_Maraganore
gptkb:Katherine_High
gptkb:Laura_Sepp-Lorenzino
gptkb:Laura_Stoppel
gptkb:Moncef_Slaoui
Eliana Clark
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:notableAchievement
|
first to demonstrate CRISPR gene editing in humans in vivo
|
|
gptkbp:numberOfEmployees
|
over 400
|
|
gptkbp:platform
|
gptkb:CRISPR/Cas9
|
|
gptkbp:product
|
gptkb:NTLA-2001
gptkb:NTLA-2002
gptkb:NTLA-5001
|
|
gptkbp:researchArea
|
immunology
oncology
genetic diseases
rare diseases
|
|
gptkbp:SECfiling
|
gptkb:10-K
|
|
gptkbp:specializesIn
|
ex vivo gene editing
in vivo gene editing
|
|
gptkbp:stockSymbol
|
gptkb:NASDAQ
gptkb:NTLA
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.intelliatx.com/
|
|
gptkbp:bfsParent
|
gptkb:Jennifer_Doudna
|
|
gptkbp:bfsLayer
|
4
|